Evaluating the Efficacy of Ragweed-SPIRE Following Exposure to Ragweed Allergen in an Environmental Exposure Chamber

Exclusion Criteria

• •Subjects with a history of ragweed pollen induced asthma
• •A history of anaphylaxis to ragweed allergen.
• •FEV1 \< 80 % of predicted.
• •Subjects who cannot tolerate Baseline Challenge in the EEC.
• •Subjects for whom administration of epinephrine is contraindicated (e.g. subjects with acute or chronic symptomatic coronary heart disease or severe hypertension).
• •History of immunopathological diseases (e.g. multiple sclerosis) that in the opinion of the Investigator or the Sponsor could interfere with the results obtained from the study.
• •A history of severe drug allergy, severe angioedema or anaphylactic reaction to food.
• •A history of any significant disease or disorder (e.g. cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, neoplastic/malignant, psychiatric, major physical impairment)